ENANTA PHARMACEUTICALS, INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
ENANTA PHARMACEUTICALS, INC (ENTA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $17.00 thousand for the 12-month period ending 2025-09-30, per its 10-K filed 2025-11-19.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2025-11-19
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $17.00K, a 81.72% decline from fiscal 2024.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $93.00K, a 97.18% decline from fiscal 2023.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $3.29M, a 81.33% decline from fiscal 2022.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $17.65M, a 552.74% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2025-09-30 | $17.00K 10-K · filed 2025-11-19 |
| 2024-09-30 | $93.00K 10-K · filed 2025-11-19 |
| 2023-09-30 | $3.29M 10-K · filed 2025-11-19 |
| 2022-09-30 | $17.65M 10-K · filed 2024-11-27 |
| 2021-09-30 | $2.70M 10-K · filed 2023-11-22 |
| 2020-09-30 | $7.85M 10-K · filed 2022-11-23 |
| 2019-09-30 | $13.86M 10-K · filed 2021-11-24 |
| 2018-09-30 | $14.18M 10-K · filed 2020-11-25 |
| 2017-09-30 | $1.50M 10-K · filed 2019-11-27 |
| 2016-09-30 | $7.71M 10-K · filed 2018-11-29 |
| 2015-09-30 | $4.83M 10-K · filed 2017-12-11 |
| 2014-09-30 | $3.22M 10-K · filed 2016-12-09 |
| 2013-09-30 | $7.57M 10-K · filed 2015-12-11 |
| 2012-09-30 | $606.00K 10-K · filed 2014-12-11 |
| 2011-09-30 | $10.00K 10-K · filed 2013-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |